Knights of Columbus Asset Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.29M	Sell	153,286 -27,585	-15%	-$423K	0.16%	137
2026 Q1	$2.51M	Buy	180,871 +43,541	+32%	+$694K	0.14%	162
2025 Q4	$2.23M	Sell	137,330 -54,077	-28%	-$883K	0.13%	175
2025 Q3	$2.86M	Buy	+191,407	New	+$2.33M	0.16%	140

Other funds holding ADPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Knights of Columbus Asset Advisors's ADPT Position: Q2 2026 in Review

Knights of Columbus Asset Advisors reduced its Adaptive Biotechnologies (ADPT) stake by 15% in Q2 2026, selling an estimated $423K and leaving 153,286 shares worth $3.29M. The position accounts for 0.16% of the portfolio, ranked #137.

Knights of Columbus Asset Advisors first reported a position in ADPT in Q3 2025 and has held it in 4 quarters since. 123 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Knights of Columbus Asset Advisors held 153,286 shares of Adaptive Biotechnologies worth $3.29M as of Q2 2026.
Knights of Columbus Asset Advisors sold 27,585 Adaptive Biotechnologies shares in Q2 2026, an estimated $423K.
Adaptive Biotechnologies made up 0.16% of Knights of Columbus Asset Advisors's portfolio in Q2 2026, its #137 holding.
Knights of Columbus Asset Advisors first reported a position in Adaptive Biotechnologies in Q3 2025 and has held it in 4 quarters since.
123 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.